Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » In Cancer Treatment, Quality of Life Matters More and More
Clinical Breakthroughs

In Cancer Treatment, Quality of Life Matters More and More

By Kristin SamuelsonJan 13, 2022
Share
Facebook Twitter Email

Study found fewer side effects from new, more effective chemotherapy

David Cella, PhD, chair of Medical Social Sciences and lead author of the study.

Google “chemotherapy side effects” and the results abound. Nausea, anemia, infection, fertility problems, kidney problems, mouth sores. The list goes on and on.

The seemingly inevitable downside of treating one’s cancer always seems to be a reduction in their quality of life. But a new Northwestern Medicine study published in Lancet Oncology found that a new combination immune therapy treatment not only extended cancer patients’ lives better than other treatments, it also was less toxic to their overall health than other drugs on the market, providing an added quality-of-life benefit.

“Historically in cancer, most new treatments that extend survival come at a cost,” said lead author David Cella, PhD, chair of Medical Social Sciences. “In this study, we found it’s actually easier on patients, so it has the double benefit.

The quality-of-life study follows an earlier New England Journal of Medicine (NEJM) study, which found a combination chemotherapy treatment of nivolumab plus cabozantinib doubled the survival rate in patients with previously untreated advanced renal-cell carcinoma when compared to the current standard first-line treatment with sunitinib.

The current Lancet Oncology study examined patient-reported symptoms and side effects from that study. It found those who were given the new treatment, nivolumab plus cabozantinib (experimental), reported their symptoms were stable or had improved while on the treatment, while those taking the existing treatment, sunitinib (control), reported a deterioration in their health status and being bothered by side effects.

“Immune therapy is revolutionizing the treatment of advanced kidney cancer,” Cella said. “For the first time in decades, we are seeing benefits to both survival and quality of life with these new treatments.” People with kidney cancer have more effective treatment options than ever before. Not only are they living longer, they are living better.”

Cella is also associate director for cancer prevention and control research at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

Funding for the study was provided by Bristol Myers Squibb in collaboration with Ono Pharmaceutical and with Exelixis, Ipsen Pharma and Takeda Pharmaceutical.

Cancer Press Release Public Health Research
Share. Facebook Twitter Email

Related Posts

Investigating Drug Combinations for Heart Failure

Dec 1, 2023

Comparing Cardiac Monitoring Methods to Detect Atrial Fibrillation After Stroke

Nov 30, 2023

Using Gene Expression to Predict if a Brain Tumor is Likely to Grow Back

Nov 29, 2023

Comments are closed.

Latest News

Investigating Drug Combinations for Heart Failure

Dec 1, 2023

Comparing Cardiac Monitoring Methods to Detect Atrial Fibrillation After Stroke

Nov 30, 2023

Using Gene Expression to Predict if a Brain Tumor is Likely to Grow Back

Nov 29, 2023

Immigrants Living in the U.S. Have Fewer Preterm Births

Nov 28, 2023

Feinberg Investigators Recognized on 2023 ‘Highly-Cited’ List

Nov 27, 2023
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
2023-Sim-Open-House_161
2023-Sim-Open-House_127
2023-Sim-Open-House_108
2023-Sim-Open-House_106
2023-Sim-Open-House_118
2023-Sim-Open-House_068
2023-Sim-Open-House_069
2023-Sim-Open-House_027
2023-Sim-Open-House_155
2023-Sim-Open-House_161
2023-Sim-Open-House_127
2023-Sim-Open-House_108

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2023 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.